Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederendpts.com
ENDPOINTS NEWS
Get the latest updates from ENDPOINTS NEWS directly as they happen.
Follow now 170 followers
Latest posts
Last updated about 4 hours ago
Teva expects to make Q3 decision on sale of API unit, CEO says
about 4 hours ago
Teva is in advanced talks to divest its active pharmaceutical ingredients unit...
Hospitals resume Sarepta’s gene therapy, but brace for coverage hurdles
about 4 hours ago
For weeks, Katie Yoder was glued to headlines tracking the FDA’s back-and-forth...
Prasad's exit seen as positive for some biotechs, but uncertainty remains
about 4 hours ago
The abrupt departure of CBER Director Vinay Prasad on Tuesday could be...
CDER director Tidmarsh will be acting head of FDA biologics center following Prasad exit
about 7 hours ago
The FDA’s new top drug regulator will also serve as acting director...
New data for Alzheimer’s drugs raise hopes, and questions, about bigger benefits over time
about 8 hours ago
TORONTO — Two studies following Alzheimer’s patients for several years after starting...
Merck to discontinue drug from Pandion deal; Coya's IND for ALS drug is delayed
about 9 hours ago
Plus, news about Vyne Therapeutics, Aclaris Therapeutics, Dx&Vx, Larimar Therapeutics, Incannex and...
KKR buys HealthCare Royalty Partners as firm deepens bet on life sciences
about 9 hours ago
KKR, one of the world's largest investment firms, has acquired a majority...
How CEO Stephen Hemsley plans to turn around a struggling UnitedHealth
about 9 hours ago
UnitedHealth Group officials on Tuesday laid out plans to right-size the healthcare...
Cardiff’s targeted therapy shows early promise in KRAS-mutated colorectal cancers
about 10 hours ago
Cardiff Oncology reported that adding a high dose of its experimental candidate...
GSK reaffirms goal of bringing Blenrep to US, reports fail with TIM-3 inhibitor
about 12 hours ago
GSK CEO Emma Walmsley said the company is steadfast in bringing Blenrep...
Madrigal licenses preclinical GLP-1 from CSPC for $120M upfront
about 12 hours ago
Madrigal Pharmaceuticals will spend $120 million upfront to license a GLP-1 agonist...
Viridian inks Japan licensing deal as it seeks to rival Amgen's Tepezza
about 16 hours ago
Viridian Therapeutics has found a partner in Japan, one of the largest...